Shares of Sanofi India Ltd. opened as much as 4% lower on Thursday, February 16, following the company's disappointing December quarter earnings announcement. According to reports from CNBC TV18, the market reaction reflected investor concerns over the pharmaceutical company's continued revenue decline and margin compression. The stock price testing levels near its 52-week low, trading around ₹4,008 on February 26, 2026, highlighting the severity of investor concerns about the company's operational performance.
The drugmaker reported a 32% year-on-year decline in net profit to ₹61.7 crore for the December quarter, compared with ₹91.3 crore in the same period last year. As reported by CNBC TV18, revenue for the quarter fell 18% to ₹420 crore from ₹515 crore a year ago, marking the third consecutive quarter of declining revenue growth for the company. This performance contrasts sharply with the broader Indian pharmaceutical sector's expected growth of 7-9% in 2026, signaling company-specific headwinds that diverge from industry trends.
Operating margins contracted significantly during the quarter, with the company's margin declining by 130 basis points to 21.6%, compared with 22.9% in the corresponding quarter last year. According to CNBC TV18, margins during the quarter were the lowest since December 2023, adding to investor concerns about the company's operational efficiency. The margin compression, coupled with declining revenues, suggests challenges in managing costs or pricing power relative to peers in the pharmaceutical industry.
Analyst sentiment towards Sanofi India remains mixed, with some brokerage firms maintaining 'Buy' or 'Add' ratings with price targets ranging from ₹6,200 to ₹9,170, while others have issued downgrades such as UBS in January 2026. The consensus rating has been described as 'Neutral' by some analysts. For the full fiscal year 2025, the company reported a 4% rise in Profit After Tax to ₹3,267 million despite an 8.7% revenue decline, partially attributed to a contract cessation with Zentiva. The company declared a final dividend of ₹48 per share for FY25, signaling some level of management confidence in its financial health despite current sales pressures.
Sanofi India's financial results present a significant divergence from the broader positive outlook for the Indian pharmaceutical sector. The company's 18% revenue decline in the December quarter is compounded by poor sales growth of -8.74% over the past five years, contrasting sharply with the pharmaceutical industry's average earnings growth of 14.4%. The company's Price-to-Earnings ratio of 26.4x to 29.6x appears elevated compared to competitors like Novartis India (19.1x) and Cipla (22.5x), indicating a potential valuation premium that may be difficult to justify given its current performance trajectory. While the company maintains strong Return on Equity figures around 43-49%, its declining revenue and profit growth present concerning backdrop for investors.
